1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015

HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015" provides an overview of HIV-Associated Lipodystrophy Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on HIV-Associated Lipodystrophy Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

HIV-Associated Lipodystrophy Syndrome Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Clinical Trials by G7 Countries: Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials 13
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 52

List of Tables
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Region, 2015* 6
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 14
HIV-Associated Lipodystrophy Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
HIV-Associated Lipodystrophy Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 17
HIV-Associated Lipodystrophy Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
HIV-Associated Lipodystrophy Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Phase, 2015* 20
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
HIV-Associated Lipodystrophy Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials, G7 Countries (%), 2015* 13
HIV-Associated Lipodystrophy Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
HIV-Associated Lipodystrophy Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of HIV-Associated Lipodystrophy Syndrome to Metabolic Disorders Clinical Trials, E7 Countries (%), 2015* 17
HIV-Associated Lipodystrophy Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
HIV-Associated Lipodystrophy Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
HIV-Associated Lipodystrophy Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
HIV-Associated Lipodystrophy Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
HIV-Associated Lipodystrophy Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
HIV Diagnosis Market by Test Type, Viral Load, CD4 Count, Early Infant, Viral Identification, Product, End User - Global Forecast to 2021

HIV Diagnosis Market by Test Type, Viral Load, CD4 Count, Early Infant, Viral Identification, Product, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The HIV diagnosis market is projected to reach USD 3.88 billion by 2021 from USD 2.35 billion in 2016, at a CAGR of 10.5% from 2016 to 2021. The global HIV diagnosis market is segmented based on product, ...

2017 World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

2017 World Blood Typing, Grouping and Infectious Disease NAT Screening Market: Sales and Market Shares of Major Suppliers by Test and Country

  • $ 5450
  • Industry report
  • March 2017
  • by Venture Planning Group

This unique report from VPGMarketResearch provides sales and market share estimates for major suppliers of blood typing, grouping and infectious disease screening products by test and country. The report ...

2017 Roche: Diagnostics Sales, Market Shares and Competitive Position by Product and Country

2017 Roche: Diagnostics Sales, Market Shares and Competitive Position by Product and Country

  • $ 5000
  • Industry report
  • March 2017
  • by Venture Planning Group

This unique market intelligence report from VPGMarketResearch provides information not available from any other published source. The report includes diagnostics sales and market share estimates by product ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.